

cover the required extension fee. The Assistant Commissioner is hereby authorized to charge any additional fee which may be due in connection with this Petition to Deposit Account No. 23-1703.

Please amend the application as follows:

In the Specification:

On page 3, line 5, delete "cognative" and substitute --cognitive-- therefor.

In the claims:

Cancel claim 1.

4. (twice amended) The salt according to claim [1] 2 in
[substantially] crystalline form.

5. (twice amended) A pharmaceutical formulation containing, as active ingredient, the salt according to any one of claims [1 to 3 or 18] 2 to 4 or 19 in association with a suitable diluent, excipient or an inert carrier.

Cancel claim 11.

12. (thrice amended) A method for [the prevention or] the treatment of [CNS] 5-hydroxytryptamine_{1A}-receptor-antagonist-activity-related central nervous system disorders[,] or so related thermoregulatory disturbances, sexual disturbances, disturbances in the cardiovascular system [and] or disturbances in the gastrointestinal system comprising [administration] administering, to a host in need of such [prevention or] treatment, an effective amount of the salt according to any one of claims [1 to 3 or 18] 2 to 4 or 19.

13. (thrice amended) A method according to claim [11] 12 for [the prevention or] the treatment of [5-HT_{1A}-receptor-antagonist-activity-related CNS disorders, thermoregulatory disturbances, sexual disturbances, disturbances in the cardiovascular system and disturbances in the gastrointestinal system] obsessive-compulsive disorder, anorexia, bulimia, senile dementia, migraine, stroke, Alzheimer's disease, cognitive disorders, pre-menstrual syndrome, hypertension or pain.

14. (amended) A method according to claim 12 for the [prevention or] treatment of depression.

15. (amended) A method according to claim 12 for the

RECEIVED

[prevention or] treatment of anxiety.

DEC 22 2001

TECH CENTER 1500/2900

16. (twice amended) A process [for the manufacture] of making

the salt as defined in any one of claims [1 to 3 or 18

characterized by] 2 to 4 or 19 which comprises the following consecutive steps:

- i) dissolving (*R*) -3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide in an appropriate solvent, optionally by heating,
- ii) adding (*2R,3R*)-tartaric acid dissolved in an appropriate aqueous organic solvent or non-aqueous organic solvent,
- iii) allowing the solution obtained to stand cold to crystallize,
- iv) optionally recrystallizing in an appropriate aqueous organic solvent, if a non-aqueous organic solvent is used in step ii), to obtain the salt defined in claim [2 or 18] 3 or 19.

17. (thrice amended) A process [for the manufacture] of making

the salt as defined in claim [2 or 18] 3 or 19 which comprises a final step of recrystallizing (*R*) -3-*N,N*-dicyclobutylamino-8-